Viiv-Medicines Patent Pool deal looks beyond India for generics partners
This article was originally published in Scrip
The Medicines Patent Pool wants generics companies from around the world, not just India, to take part in the voluntary license agreement it this week announced with Viiv Healthcare (formed of GlaxoSmithKline, Shionogi and P fizer), said Greg Perry, the Pool's executive director.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.